Frontlight ResearchEarly access
Spinal muscular atrophy trials in Finland
1 trial · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in FinlandA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Helsinki
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00